Bright Minds Biosciences Inc.
HealthcareNASDAQ:DRUG · NASDAQ Capital Market
-$0.62 today
Vol 0.66M · Avg 0.24M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-14.9%
avg -87.9%
ROIC
-17.0%
avg -87.6%
ROA
-14.5%
avg -76.2%
Analysis
ROA is currently the strongest return metric at -14.5% versus its period average of -76.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jan Torleif Pedersen | Chief Science Officer & Director | $523,211.00 | — | 61 | — | — |
Stephen D. Collins | Chief Medical Officer | $227,375.00 | — | 73 | — | — |
Ryan E. S. K. Cheung | CFO & Corporate Secretary | $96,119.00 | — | 48 | — | — |
Alex Vasilkevich | Chief Operating Officer & Senior Scientific Officer | — | — | 37 | — | — |
Ian McDonald | Co-Founder, Chief Executive Officer, President & Director | — | — | 38 | — | — |
Emer Leahy | Consultant | — | — | 59 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
1
$9.79M
Net Sentiment
$9.79M
Net selling
Most Active
Cormorant Asset Management, LP
1 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Apr 28, 2026 | Cormorant Asset Management, LP Indirect | Sell | 109.3K | $89.50 | $9,785,124.50 |
Analysis
Insiders reported 0 buys worth $0.00 and 1 sells worth $9.79M over the last 12 months. That adds up to net selling of $9.79M. Cormorant Asset Management, LP was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Design Therapeutics, Inc.
NASDAQ:DSGN
$685.15M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Aura Biosciences, Inc.
NASDAQ:AURA
$411.52M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
I-Mab
IMAB
$235.66M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Galectin Therapeutics Inc.
NASDAQ:GALT
$175.84M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages DRUG?
Bright Minds Biosciences Inc. (DRUG) lists 6 active executives. The top listed executive is Jan Torleif Pedersen, Chief Science Officer & Director.
Are DRUG insiders buying or selling?
Recent insider activity shows net selling of $2.55M.
Explore More
Continue the stock analysis
Jump to another research area for this company.